Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
Status:
Not yet recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
Pulse is a randomized non-inferiority phase III clinical trial assessing a new mode of
immunotherapy administration based on increased interval time between 2 infusions as
maintenance treatment in Pulse arm compared with the conventional administration in Control
arm.
In both treatment arms, pembrolizumab alone or combined with pemetrexed is allowed as
maintenance treatment. Indeed :
In Pulse arm : Pembrolizumab 200 mg will be administered to patients every 6 weeks (Q6W)
plus, in the absence of contra-indication pemetrexed 500 mg/m^2 will be administered every 3
weeks (Q3W).
In control arm : Pembrolizumab 200 mg will be administered to patients every 3 weeks (Q3W) or
400 mg every 6 weeks plus,in the absence of contra-indication pemetrexed 500 mg/m^2 will be
administered every 3 weeks (Q3W).